Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients
Open Access
- 16 October 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0186200
Abstract
Isoniazid (INH) is part of the first-line-therapy for tuberculosis (TB) but can cause drug-induced liver injury (DILI). Several candidate single nucleotide polymorphisms (SNPs) have been previously identified but the clinical utility of these SNPs in the prediction of INH-DILI remains uncertain. The aim of this study was to assess the association between selected candidate SNPs and the risk of INH-DILI and to assess the clinical validity of associated variants in a Singaporean population. This was a case-control study where 24 INH-DILI cases and 79 controls were recruited from the TB control unit in a tertiary hospital. Logistic regression was used to test for the association between candidate SNPs and INH-DILI. NAT2 acetylator status was inferred from genotypes and tested for association with INH-DILI. Finally, clinical validity measures were estimated for significant variants. Two SNPs in NAT2 (rs1041983 and rs1495741) and NAT2 slow acetylators (SA) were significantly associated with INH-DILI (OR (95% CI) = 13.86 (4.30–44.70), 0.10 (0.03–0.33) and 9.98 (3.32–33.80), respectively). Based on an INH-DILI prevalence of 10%, the sensitivity, specificity, positive and negative predictive values of NAT2 SA were 75%, 78%, 28% and 97%, respectively. The population attributable fraction (PAF) and number needed to test (NNT) for NAT2 SA were estimated to be 0.67 and 4.08, respectively. A model with clinical and NAT2 acetylator status provided significantly better prediction for INH-DILI than a clinical model alone (area under receiver operating characteristic curve = 0.863 vs. 0.766, respectively, p = 0.027). We show the association between NAT2 SA and INH-DILI in a Singaporean population and demonstrated its clinical utility in the prediction of INH-DILI.Keywords
Funding Information
- Biomedical Research Council, Agency for Science Technology and Research (SPF2014/001)
- Canadian Institutes of Health Research
- Michael Smith Health Research BC
This publication has 58 references indexed in Scilit:
- Cytochrome P450 2E1 Gene Polymorphisms/Haplotypes and Anti-Tuberculosis Drug-Induced Hepatitis in a Chinese CohortPLOS ONE, 2013
- NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapyEuropean Journal of Clinical Pharmacology, 2012
- An integrated map of genetic variation from 1,092 human genomesNature, 2012
- Genetic variants in antioxidant pathway: Risk factors for hepatotoxicity in tuberculosis patientsTuberculosis, 2012
- Accuracy of Various Human NAT2 SNP Genotyping Panels to Infer Rapid, Intermediate and Slow Acetylator PhenotypesPharmacogenomics, 2011
- Role of polymorphic N‐acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment‐induced hepatitisJournal of Gastroenterology and Hepatology, 2011
- A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility lociNature Genetics, 2010
- Singapore Genome Variation Project: A haplotype map of three Southeast Asian populationsGenome Research, 2009
- So Many Correlated Tests, So Little Time! Rapid Adjustment of P Values for Multiple Correlated TestsThe American Journal of Human Genetics, 2007
- Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patientsJournal of Gastroenterology and Hepatology, 2006